Peptides Similar to Bivamelagon
Compare Bivamelagon with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Setmelanotide: Very high - Both are MC4R agonists for rare obesity indications
- •Semaglutide: Low - Both treat obesity but via entirely different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Bivamelagon (current) | - | - |
| Setmelanotide | Very high - Both are MC4R agonists for rare obesity indications | Setmelanotide is an injectable cyclic peptide approved for genetic obesity (POMC, PCSK1, LEPR). Bivamelagon is an oral small molecule for hypothalamic obesity. |
| Semaglutide | Low - Both treat obesity but via entirely different mechanisms | Semaglutide targets GLP-1 receptors for general obesity. Bivamelagon targets MC4R for hypothalamic obesity specifically. |
| Tirzepatide | Low - Both treat obesity but different mechanisms and populations | Tirzepatide is a dual GLP-1/GIP agonist for general obesity. Bivamelagon specifically targets hypothalamic obesity via MC4R. |
SetmelanotideVery high - Both are MC4R agonists for rare obesity indications
Differences
Setmelanotide is an injectable cyclic peptide approved for genetic obesity (POMC, PCSK1, LEPR). Bivamelagon is an oral small molecule for hypothalamic obesity.
Advantages
FDA-approved, proven efficacy in genetic obesity, established safety profile
Disadvantages
Requires daily injection; approved for genetic obesity only, not hypothalamic obesity
SemaglutideLow - Both treat obesity but via entirely different mechanisms
Differences
Semaglutide targets GLP-1 receptors for general obesity. Bivamelagon targets MC4R for hypothalamic obesity specifically.
Advantages
FDA-approved, well-studied, proven efficacy in general obesity
Disadvantages
GLP-1 agonists are often less effective in hypothalamic obesity due to disrupted central appetite regulation
TirzepatideLow - Both treat obesity but different mechanisms and populations
Differences
Tirzepatide is a dual GLP-1/GIP agonist for general obesity. Bivamelagon specifically targets hypothalamic obesity via MC4R.
Advantages
FDA-approved, strong weight loss efficacy in general population
Disadvantages
Injectable; may be less effective in hypothalamic obesity
Agents Related to Bivamelagon#
Bivamelagon is unique as the first oral MC4R agonist for hypothalamic obesity. Its closest comparator is setmelanotide, which targets the same receptor but for a different indication and via a different route.
| Feature | Bivamelagon | Setmelanotide | Semaglutide |
|---|---|---|---|
| Type | Small molecule | Cyclic peptide | Acylated peptide |
| Target | MC4R | MC4R | GLP-1R |
| Route | Oral daily | SC daily | SC weekly / oral |
| Indication | Hypothalamic obesity | Genetic obesity | General obesity |
| BMI/Weight loss | -9.3% BMI (14 wk) | Variable by genotype | 14.9% weight (68 wk) |
| Population | Ages 12+ | Ages 6+ | Adults |
| Regulatory | Phase 2 | Approved | Approved |
Comparison Context#
Bivamelagon belongs to the Metabolic category of research peptides. Comparing Bivamelagon with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Bivamelagon in mechanism, indication, or therapeutic category:
Bivamelagon vs Setmelanotide#
Similarity: Very high - Both are MC4R agonists for rare obesity indications
Key Differences: Setmelanotide is an injectable cyclic peptide approved for genetic obesity (POMC, PCSK1, LEPR). Bivamelagon is an oral small molecule for hypothalamic obesity.
Advantages of Setmelanotide: FDA-approved, proven efficacy in genetic obesity, established safety profile
Disadvantages of Setmelanotide: Requires daily injection; approved for genetic obesity only, not hypothalamic obesity
Researchers choosing between Bivamelagon and Setmelanotide should consider the development stage, available evidence, and specific research objectives when making their selection.
Bivamelagon vs Semaglutide#
Similarity: Low - Both treat obesity but via entirely different mechanisms
Key Differences: Semaglutide targets GLP-1 receptors for general obesity. Bivamelagon targets MC4R for hypothalamic obesity specifically.
Advantages of Semaglutide: FDA-approved, well-studied, proven efficacy in general obesity
Disadvantages of Semaglutide: GLP-1 agonists are often less effective in hypothalamic obesity due to disrupted central appetite regulation
Researchers choosing between Bivamelagon and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Bivamelagon vs Tirzepatide#
Similarity: Low - Both treat obesity but different mechanisms and populations
Key Differences: Tirzepatide is a dual GLP-1/GIP agonist for general obesity. Bivamelagon specifically targets hypothalamic obesity via MC4R.
Advantages of Tirzepatide: FDA-approved, strong weight loss efficacy in general population
Disadvantages of Tirzepatide: Injectable; may be less effective in hypothalamic obesity
Researchers choosing between Bivamelagon and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Bivamelagon
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer